Stay updated on Omalizumab in Multi-Allergen OIT Clinical Trial
Sign up to get notified when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.

Latest updates to the Omalizumab in Multi-Allergen OIT Clinical Trial page
- Check4 days agoChange DetectedThe webpage has added helpful links provided by the National Institute of Allergy and Infectious Diseases (NIAID), which may enhance the resourcefulness of the page.SummaryDifference0.1%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.2%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.2%
- Check40 days agoChange DetectedNew data has been added regarding the proportion of participants able to consume various amounts of food protein without dose-limiting symptoms during double-blind placebo-controlled oral food challenges, particularly after treatment with omalizumab and omalizumab-facilitated oral immunotherapy, while previous updates and specific data points have been removed.SummaryDifference5%
- Check54 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check62 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.0%
Stay in the know with updates to Omalizumab in Multi-Allergen OIT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.